Financial Performance - For the nine months ended September 30, 2025, the company's operating revenue was RMB 6,762,620,901.32, representing a year-on-year increase of 0.42% compared to RMB 6,734,166,240.75 in the same period of 2024[6] - The net profit attributable to shareholders of the listed company for the same period was RMB 256,220,710.12, a decrease of 25.53% from RMB 344,079,950.67 in 2024[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 239,056,816.15, down 25.62% from RMB 321,411,536.21 in the previous year[6] - The basic and diluted earnings per share were both RMB 0.37, down 26.00% from RMB 0.50 in the previous year[7] - The comprehensive income attributable to shareholders of the parent company was RMB 251,366,971.67, down from RMB 419,303,408.85 in the same period last year[9] Cash Flow and Assets - The net cash flow from operating activities increased by 26.65% to RMB 321,998,862.97, compared to RMB 254,240,659.40 in the same period last year[7] - The total assets as of September 30, 2025, were RMB 9,093,740,128.02, reflecting a 0.82% increase from RMB 9,019,601,567.53 at the end of 2024[7] - The net assets attributable to shareholders of the listed company increased by 3.15% to RMB 5,149,027,624.51 from RMB 4,991,588,524.78 at the end of 2024[7] Operating Costs and Expenses - The total operating costs for the nine months ended September 30, 2025, were RMB 6,434,132,318.50, compared to RMB 6,337,089,365.67 in the same period of 2024[8] - The company's research and development expenses for the period were RMB 300,109,321.29, a decrease from RMB 326,669,940.69 in the previous year[8]
山东新华制药股份(00719) - 2025 Q3 - 季度业绩